BLTE Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -82.06%. Belite Bio, Inc.'s return on equity of -37.13% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 2.27%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 4.82%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Belite Bio, Inc.'s net income of -$21.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 14.73x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of 10.18%. Belite Bio, Inc.'s return on equity of -37.13% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 2.27%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 27.83%. Given that Ligand Pharmaceuticals, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ligand Pharmaceuticals, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Belite Bio, Inc.'s net income of -$21.7M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 91.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 14.92x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -1144.46%. Belite Bio, Inc.'s return on equity of -37.13% beat Ocugen, Inc.'s return on equity of -345.08%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 2.27%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 576.69%. Given that Ocugen, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ocugen, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 3.493, suggesting its more volatile than the S&P 500 by 249.3%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Belite Bio, Inc.'s net income of -$21.7M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 73.00x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of --. Belite Bio, Inc.'s return on equity of -37.13% beat Terns Pharmaceuticals, Inc.'s return on equity of -29.05%.

Belite Bio, Inc. has a consensus price target of $186.50, signalling upside risk potential of 2.27%. On the other hand Terns Pharmaceuticals, Inc. has an analysts' consensus of $58.13 which suggests that it could grow by 53.89%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Terns Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Terns Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Terns Pharmaceuticals, Inc. quarterly revenues of --. Belite Bio, Inc.'s net income of -$21.7M is higher than Terns Pharmaceuticals, Inc.'s net income of -$24.6M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Terns Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus -- for Terns Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.